Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
UNIVEC announces entry into Transdermal Patch Marketplace
Jan 16, 2012
OTC Disclosure & News Service
Owings Mills, MD -
Contact:
David Dalton, President
E-mail univec@univecinc.com
UNIVEC announces entry into Transdermal Patch Marketplace.
Owings Mills, Maryland —January 17, 2012– Univec, Inc. (UNVC) a specialty pharmaceutical company, announces it has entered into the transdermal patch marketplace with the provision of Nicotine Replacement Therapy patches. Nicotine Replacement Therapy involves the use of products that provide low doses of nicotine but do not contain the toxins found in smoke. The goal is to relieve cravings for nicotine and ease the symptoms when someone stops using cigarettes and smokeless tobacco. Transdermal patch is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream.
David L. Dalton, President and CEO of Univec stated. “ We are delighted to continue making progress in our new business model. The National Drug Codes received from the FDA allows Univec to builds it’s own brand of products. The Transdermal patch can be used for different drug delivery system. It is a foundation to build and grow the company on some of our existing markets. We thank our associates, shareholders and investors for the support, confidence and patience they have shown the company. ”
About Univec
Univec, Inc. A minority business enterprise (MBE) is a Specialty Pharmaceutical Company that manufactures and distributes high cost Specialty Pharmaceuticals. Specialty Pharmaceuticals are high cost products that are not usually dispensed in retail pharmacies but require special handling and a complex pharmaceutical regime. The company is focused on diseases such as Sickle Cell Anemia, Cancer, HIV/Aids, Hepatitis C., Multiple Sclerosis, Hemophilia and Drug addiction.
PPSI (PHYSICIAN AND PHARMACEUTICAL SERVICES, INC.) a subsidiary of Univec promotes and pays for pharmaceutical products though its network of pharmacies. PPSI eliminates the need for the pharmaceutical companies to distribute actual drug samples to physicians reducing potential liability for the physician while maintaining clinical oversight and drug interaction checks for the patient. The company through it’s “StarterScript” allows in lieu of a physician sample, a voucher or a co-payment card to be provide to the patient for a trial supply of medication redeemed in any of the nearly 55,000 retail pharmacies utilizing the PPSI real-time processing system.
Forward Looking Statements
This document may contain forward-looking statements based on current expectations that could be affected by the risks and uncertainties involved in Univec’s business. These risks and uncertainties include, but are not limited to, the risks described from time to time in Univec’s reports to the General Public and reporting agencies. Subsequent written or oral statements attributable to Univec or persons acting on its behalf are expressly qualified in their entirety by the cautionary statements in this document and those in Univec’s reports filed
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
UNIVEC announces entry into Transdermal Patch Marketplace
Jan 16, 2012
OTC Disclosure & News Service
Owings Mills, MD -
Contact:
David Dalton, President
E-mail univec@univecinc.com
UNIVEC announces entry into Transdermal Patch Marketplace.
Owings Mills, Maryland —January 17, 2012– Univec, Inc. (UNVC) a specialty pharmaceutical company, announces it has entered into the transdermal patch marketplace with the provision of Nicotine Replacement Therapy patches. Nicotine Replacement Therapy involves the use of products that provide low doses of nicotine but do not contain the toxins found in smoke. The goal is to relieve cravings for nicotine and ease the symptoms when someone stops using cigarettes and smokeless tobacco. Transdermal patch is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream.
David L. Dalton, President and CEO of Univec stated. “ We are delighted to continue making progress in our new business model. The National Drug Codes received from the FDA allows Univec to builds it’s own brand of products. The Transdermal patch can be used for different drug delivery system. It is a foundation to build and grow the company on some of our existing markets. We thank our associates, shareholders and investors for the support, confidence and patience they have shown the company. ”
About Univec
Univec, Inc. A minority business enterprise (MBE) is a Specialty Pharmaceutical Company that manufactures and distributes high cost Specialty Pharmaceuticals. Specialty Pharmaceuticals are high cost products that are not usually dispensed in retail pharmacies but require special handling and a complex pharmaceutical regime. The company is focused on diseases such as Sickle Cell Anemia, Cancer, HIV/Aids, Hepatitis C., Multiple Sclerosis, Hemophilia and Drug addiction.
PPSI (PHYSICIAN AND PHARMACEUTICAL SERVICES, INC.) a subsidiary of Univec promotes and pays for pharmaceutical products though its network of pharmacies. PPSI eliminates the need for the pharmaceutical companies to distribute actual drug samples to physicians reducing potential liability for the physician while maintaining clinical oversight and drug interaction checks for the patient. The company through it’s “StarterScript” allows in lieu of a physician sample, a voucher or a co-payment card to be provide to the patient for a trial supply of medication redeemed in any of the nearly 55,000 retail pharmacies utilizing the PPSI real-time processing system.
Forward Looking Statements
This document may contain forward-looking statements based on current expectations that could be affected by the risks and uncertainties involved in Univec’s business. These risks and uncertainties include, but are not limited to, the risks described from time to time in Univec’s reports to the General Public and reporting agencies. Subsequent written or oral statements attributable to Univec or persons acting on its behalf are expressly qualified in their entirety by the cautionary statements in this document and those in Univec’s reports filed
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
be back in a few weeks will be traveling. GLTA.
I was doing some DD today, the wheels are turning I am all for this. Hopefully we see a PR out from Dalton soon! I think we will see above .001+ so don't be so quick on the trigger you may be surprised. GLTA.
It's amazing we have a CEO who is a certified doctor that has all these honors and achievements yet no one has heard from him in over a year. At this point I am thinking either...
A)Dalton made his fortune and wants nothing to do with Univec, Inc.
B)Dalton was caught up in the Corey Ribotsky scandel and is laying low from the authorities.
C)Dalton is flat broke, diluted the share count to pay bills and can't even find work.
D)Dalton kicked the can and might not be living
Investors which one do you think?
Ask now .0186$
someone big on bid tapping in, news coming?
If the CEO would do the following listed below we would be sitting at .001-.003+ very easily.imo.
-Put out financials
-Update shareholders
-Reason why O/S increased by 150 Million shares
These answered i would be satisfied and invest more here without hesitation.
why did the CEO dilute 153 million shares?
Can tell they are priming this for a solid PR. Holding strong, a good news release will get this rocking.
.019s printing... getting strong!
Some funny business on the bid/ask - have you noticed someone sells tiny amounts to knock the bid down to make it look like the price is dropping. Then the MM pulls the ask right back up, I think something is brewing here MM is staying strong on this. Someone wants cheap shares it's not happening! Long and strong.
remember this Citi article http://www.strategybox.com/forum/topic_details/32/5
BAC good article http://www.strategybox.com/forum/topic_details/47/5
Do what is in the best interest for you and your investment. Without a CEO to be found in over a year I don't foresee a thing happening here unless you can prove otherwise.
I will only consider averaging when Dalton communicates with his shareholders via phone, email, PR, etc. Until then not worth the risk knowing this could go to No Bid. Good luck to you.
i bought in on the .0077 rally and paid a high price, it hasn't seen my buy in price since. No interest in buying more after doing enough DD on this as I predict we could see No Bid with No CEO to be found. All the best to you, I will wait as this is a small percentage of my portfolio.
Val.
to answer your pm question. I own this stock at a pretty high price. I would rather see real developments take place (financials, revenues, company communication, marketing, etc) instead of some forum posters just running this up a few ticks then watching it crash again and again (watched this for a year now it gets old). Only REAL developments/revenue from the company at this point will possibly get me back to where I bought in. As of right now this is an empty shell, no ceo, no revenue, no nothing until proven otherwise.
18's up, heading back up.
go ahead buy i will watch.
Please. Let me know if you ever hear from Dalton, that website is useless garbage.
I am long here, my positions are pretty diversified now so if I have to wait months/years on this one so be it I will never sell for a loss.
I highly doubt you will ever hear anything, when and if you do please update the board.
Meritage,
Have you had any communication with Univec or David Dalton at all? Do you predict anything ever happening here?
Value,
have you had any communication with Univec, Inc or David Dalton at all?
base is building, looks like the bottom here, could see mid 2's today!
Is this big news?
Jan 10th - Allezoe Medical Holdings (ALZM) Announces New Acquisition Agreement for Decontamination System
BOCA RATON, FLORIDA, Jan 10, 2012 (MARKETWIRE via COMTEX) -- Allezoe Medical Holdings, Inc. (OTCBB: ALZM) announced that it has entered into an agreement to acquire the decontamination technology licensing and development business of BioCube, Inc. (OTCBB: BICB) in exchange for convertible preferred stock of Allezoe plus the cancellation of the existing 60 percent non-dilution provision relating to the Company's common stock, issued in connection with the acquisition of Organ Transport Systems, Inc. The preferred stock to be issued will carry a 51 percent of the shareholder vote and will be convertible after one year at the discretion of the holder into 51 percent of the common stock. The transaction will be completed in the next 30 days through the acquisition of a wholly-owned Nevada subsidiary of BioCube.
BioCube is collaborating with its Russian research partners to complete the development and commercialization of an environmentally safe decontamination system, utilizing an aerosol-based delivery method. This system has demonstrated effective handling of microbial and fungal cells, spores, and viruses that are the core of such infections as MRSA, Avian Flu, Swine Flu and common molds.
Allezoe CEO Michael Gelmon stated: "Hospitals struggle with the control of infectious diseases and continue to look for efficient, environmentally friendly, and cost-effective means of dealing with this pervasive problem. BioCube focuses on this existing market need for decontamination of patient rooms, operating theaters, medical equipment and furniture, which exists in over 5,000 hospitals and nearly 1 million beds in the U.S. healthcare system, as well as the many other uses of a similar decontamination solution."
BioCube will focus on the following target markets:
-- Healthcare (hospital, nursing homes)
-- Travel (airplanes, cruise ships, mobile homes)
-- Mold remediation
-- Schools
-- Animal farming
-- Agriculture
BioCube believes that its decontamination technology holds significant promise as a long-term solution to a global problem. BioCube's objective is to help create an effective technology that will allow for rapid, inexpensive and environmentally safe remediation of buildings that have been contaminated by a biological agent, thus allowing a speedy return to a state of normalcy.
According to Mr. Gelmon: "With the acquisition of the decontamination technology, Allezoe will have three active subsidiaries with medical device products in development. Organ Transport Systems, Inc. continues the development work needed to begin its FDA clearance process for the Life Cradle(TM) organ transport system for transplants; SureScreen(TM) Medical has started the last stages of development of the "see and treat" technology for Human Papilloma virus (HPV), the world's leading sexually transmitted infection (STI); and our new subsidiary, BioCube, Inc., will complete the development process and start the marketing and distribution of the aerosol based, environmentally friendly decontamination system. This means we will expect to have three new medical technologies coming to the market over the next 6 to 15 months, and we will continue to seek medical device development and manufacturing companies to enhance our current portfolio."
About Allezoe Medical Holdings
Allezoe Medical Holdings, Inc. (OTCBB: ALZM) is a holding company focused on acquiring the most high quality and in-demand medical products, solutions and services. Whether through diagnosis, treatment, or medical research itself, Allezoe is interested in companies that are making a striking difference in the healthcare system through technology and treatments for health issues that affect large populations. For more information, please visit www.allezoe.com.
Safe Harbor Statement
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21 E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that these forward-looking statements involve uncertainties and risk that could cause actual performance and results of operations to differ materially from those anticipated. These risks are set forth in the Company's most recently filed form 10-K and Form 10-Q reports. The Company assumes no obligation to update the statements contained in this release except as required by applicable securities disclosure rules. The Company's SEC filings are available at www.sec.gov.
Contacts:
Allezoe Medical Holdings, Inc.
Media Department
media@allezoe.com
www.allezoe.com
SOURCE: Allezoe Medical Holdings, Inc.
CONTACT: mailto:media@allezoe.com
http://www.allezoe.com
Copyright 2012 Marketwire, Inc., All rights reserved.
-0-
SUBJECT CODE: Financial Services:Investment Services and Trading
Pharmaceuticals and Biotech:Biotech
Medical and Healthcare:Medical Devices
Allezoe Medical Holdings (ALZM) Announces New Acquisition Agreement for Decontamination System
BOCA RATON, FLORIDA, Jan 10, 2012 (MARKETWIRE via COMTEX) -- Allezoe Medical Holdings, Inc. (OTCBB: ALZM) announced that it has entered into an agreement to acquire the decontamination technology licensing and development business of BioCube, Inc. (OTCBB: BICB) in exchange for convertible preferred stock of Allezoe plus the cancellation of the existing 60 percent non-dilution provision relating to the Company's common stock, issued in connection with the acquisition of Organ Transport Systems, Inc. The preferred stock to be issued will carry a 51 percent of the shareholder vote and will be convertible after one year at the discretion of the holder into 51 percent of the common stock. The transaction will be completed in the next 30 days through the acquisition of a wholly-owned Nevada subsidiary of BioCube.
BioCube is collaborating with its Russian research partners to complete the development and commercialization of an environmentally safe decontamination system, utilizing an aerosol-based delivery method. This system has demonstrated effective handling of microbial and fungal cells, spores, and viruses that are the core of such infections as MRSA, Avian Flu, Swine Flu and common molds.
Allezoe CEO Michael Gelmon stated: "Hospitals struggle with the control of infectious diseases and continue to look for efficient, environmentally friendly, and cost-effective means of dealing with this pervasive problem. BioCube focuses on this existing market need for decontamination of patient rooms, operating theaters, medical equipment and furniture, which exists in over 5,000 hospitals and nearly 1 million beds in the U.S. healthcare system, as well as the many other uses of a similar decontamination solution."
BioCube will focus on the following target markets:
-- Healthcare (hospital, nursing homes)
-- Travel (airplanes, cruise ships, mobile homes)
-- Mold remediation
-- Schools
-- Animal farming
-- Agriculture
BioCube believes that its decontamination technology holds significant promise as a long-term solution to a global problem. BioCube's objective is to help create an effective technology that will allow for rapid, inexpensive and environmentally safe remediation of buildings that have been contaminated by a biological agent, thus allowing a speedy return to a state of normalcy.
According to Mr. Gelmon: "With the acquisition of the decontamination technology, Allezoe will have three active subsidiaries with medical device products in development. Organ Transport Systems, Inc. continues the development work needed to begin its FDA clearance process for the Life Cradle(TM) organ transport system for transplants; SureScreen(TM) Medical has started the last stages of development of the "see and treat" technology for Human Papilloma virus (HPV), the world's leading sexually transmitted infection (STI); and our new subsidiary, BioCube, Inc., will complete the development process and start the marketing and distribution of the aerosol based, environmentally friendly decontamination system. This means we will expect to have three new medical technologies coming to the market over the next 6 to 15 months, and we will continue to seek medical device development and manufacturing companies to enhance our current portfolio."
About Allezoe Medical Holdings
Allezoe Medical Holdings, Inc. (OTCBB: ALZM) is a holding company focused on acquiring the most high quality and in-demand medical products, solutions and services. Whether through diagnosis, treatment, or medical research itself, Allezoe is interested in companies that are making a striking difference in the healthcare system through technology and treatments for health issues that affect large populations. For more information, please visit www.allezoe.com.
Safe Harbor Statement
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21 E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that these forward-looking statements involve uncertainties and risk that could cause actual performance and results of operations to differ materially from those anticipated. These risks are set forth in the Company's most recently filed form 10-K and Form 10-Q reports. The Company assumes no obligation to update the statements contained in this release except as required by applicable securities disclosure rules. The Company's SEC filings are available at http://www.sec.gov.
Contacts:
Allezoe Medical Holdings, Inc.
Media Department
media@allezoe.com
www.allezoe.com
SOURCE: Allezoe Medical Holdings, Inc.
CONTACT: mailto:media@allezoe.com
http://www.allezoe.com
Copyright 2012 Marketwire, Inc., All rights reserved.
-0-
SUBJECT CODE: Financial Services:Investment Services and Trading
Pharmaceuticals and Biotech:Biotech
Medical and Healthcare:Medical Devices
any info on David Dalton?
I'm a shareholder of Univec, Inc (UNVC) and the CEO Dr.David Dalton has vanished months ago, Ribotsky has a few notes out to him.
http://investorshub.advfn.com/boards/board.aspx?board_id=1802
I called Gelmon Friday afternoon, he said new updates were being added to the website and it will be put back up shortly, he didn't want to say anymore then that.
Today's alerts include: Allezoe Medical Holdings, Inc. (OTCBB: ALZM)
Allezoe Medical Holdings, Inc. recently announced that it has acquired the exclusive license to develop and market patent pending, advanced "see and treat" diagnostic technology for Human papillomavirus (HPV), the world's leading sexually transmitted infection (STI). An exclusive license has been signed by SureScreen Medical, Inc., a wholly-owned subsidiary of Allezoe, and AVM Corp., which recently acquired the technology and the pending patent application from its developer, Aequorea Vision Medical, Inc.
Under the terms of the license, SureScreen will develop and market products worldwide using the technology in return for a fixed royalty to AVM, commencing on sales of products using the technology.
As a result of the license, Allezoe now holds the exclusive worldwide rights to this groundbreaking "see and treat" technology which will allow healthcare providers to identify cell damage from HPV instantaneously, bypassing the long lab wait times, fees and additional patient discomfort found in existing HPV diagnostic methods on the market, including the Pap smear.
With this license and the global marketing and distribution strategy it is developing, Allezoe will be positioned to enter its market. In the United States alone, there is a $6 billion annual diagnosis and treatment market for HPV, and the market is increasing under growing national attention to the virus. Recently, the Centers for Disease Control and Prevention has recommended the HPV vaccine be used for men as well. Allezoe's technology is a crucial counterpart to the vaccine, identifying any preexisting damage before vaccine administration; importantly, it also offers an important alternative for those who avoid the vaccine due to controversial side effects.
Infecting 233 million women worldwide, the virus is the leading cause of cervical cancer in women, which often results in death. HPV is known to cause a growing number of cancers and lesions in both genders, including cervical, neck, and throat cancer. More recently, HPV is being researched as a possible cause of heart disease. Allezoe's technology is a one-stop HPV solution for patients and their providers. Allezoe's HPV technology will be welcome in the United States, where healthcare costs are a growing concern. It has important implications for healthcare abroad and in poorer nations where patients do not have the luxury of making repeated visits to a clinic or waiting several days for a Pap smear report from a distant laboratory.
Allezoe Medical Holdings, Inc. is a holding company focused on acquiring the most high quality and in-demand medical products, solutions and services. Whether through diagnosis, treatment, or medical research itself, Allezoe is interested in companies that are making a striking difference in the healthcare system through technology and treatments for health issues that affect large populations.
For more information, please visit www.allezoe.com.
ABOUT OTC Signal
OTC Signal (www.otcsignal.com) is a stock watch website that provides free daily alerts on stocks. OTC Signal's alerts include news releases or daily e-mails on stocks in all sectors of the market. These include stocks with high or low volume, penny stocks, stocks with technical indicators and much more. OTC Signal tracks stocks that may be moving upwards or downwards. OTC Signal also features companies on its website with company profiles, research reports, analysis, and newsletters.
OTC Signal is an independent electronic publication that provides information on selected publicly traded companies. OTC Signal is not a registered investment advisor or broker-dealer. OTC Signal including affiliates, officers, directors, contractors and employees may buy, sell or hold shares in any company mentioned herein and may profit in the event those shares increase or decrease in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.
To join and start receiving our FREE e-mail alerts and newsletter, please visit: http://www.otcsignal.com
Disclaimers-
Release of Liability: Through use of this website viewing or using you agree to hold OTCSignal.com, its operators, owners, and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities.
The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTC Signal encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTC Signal makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTC Signal has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTC Signal also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in any stock (large-cap, small-cap, or micro-cap security) is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTC Signal makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCSignal.com. OTC Signal owners may or may not hold positions in any of the companies that are profiled.
SAFE HARBOR: The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. These statements are not guarantees of future performance and involve significant risks and uncertainties. Actual results may vary materially from those in the forward-looking statements. Factors that could cause actual results to differ include but are not limited to; the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, the effectiveness of management's strategies and decisions, general economic and business conditions, new or modified statutory or regulatory requirements and changing price and market conditions. Investing in securities is speculative and carries risk. Past performance does not guarantee future results. No assurance can be given that these are all the factors that could cause actual results to vary materially from the forward-looking statements. The following report is neither an offer to buy or sell securities. Never invest in any stock featured on the OTC Signal Stock Watch website unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list.
OTC Signal
Daily Alert
-
New York, NY 10001
USA
Phone: -
Note: The following news is from Daily Alert, and World Stock Wire, Inc. is not liable for the contents of this news.
(C) 2011 World Stock Wire, Inc. All rights reserved.
-0-
Today's alerts include: Allezoe Medical Holdings, Inc. (OTCBB: ALZM)
Allezoe Medical Holdings, Inc. recently announced that it has acquired the exclusive license to develop and market patent pending, advanced "see and treat" diagnostic technology for Human papillomavirus (HPV), the world's leading sexually transmitted infection (STI). An exclusive license has been signed by SureScreen Medical, Inc., a wholly-owned subsidiary of Allezoe, and AVM Corp., which recently acquired the technology and the pending patent application from its developer, Aequorea Vision Medical, Inc.
Under the terms of the license, SureScreen will develop and market products worldwide using the technology in return for a fixed royalty to AVM, commencing on sales of products using the technology.
As a result of the license, Allezoe now holds the exclusive worldwide rights to this groundbreaking "see and treat" technology which will allow healthcare providers to identify cell damage from HPV instantaneously, bypassing the long lab wait times, fees and additional patient discomfort found in existing HPV diagnostic methods on the market, including the Pap smear.
With this license and the global marketing and distribution strategy it is developing, Allezoe will be positioned to enter its market. In the United States alone, there is a $6 billion annual diagnosis and treatment market for HPV, and the market is increasing under growing national attention to the virus. Recently, the Centers for Disease Control and Prevention has recommended the HPV vaccine be used for men as well. Allezoe's technology is a crucial counterpart to the vaccine, identifying any preexisting damage before vaccine administration; importantly, it also offers an important alternative for those who avoid the vaccine due to controversial side effects.
Infecting 233 million women worldwide, the virus is the leading cause of cervical cancer in women, which often results in death. HPV is known to cause a growing number of cancers and lesions in both genders, including cervical, neck, and throat cancer. More recently, HPV is being researched as a possible cause of heart disease. Allezoe's technology is a one-stop HPV solution for patients and their providers. Allezoe's HPV technology will be welcome in the United States, where healthcare costs are a growing concern. It has important implications for healthcare abroad and in poorer nations where patients do not have the luxury of making repeated visits to a clinic or waiting several days for a Pap smear report from a distant laboratory.
Allezoe Medical Holdings, Inc. is a holding company focused on acquiring the most high quality and in-demand medical products, solutions and services. Whether through diagnosis, treatment, or medical research itself, Allezoe is interested in companies that are making a striking difference in the healthcare system through technology and treatments for health issues that affect large populations.
For more information, please visit www.allezoe.com.
ABOUT OTC Signal
OTC Signal (www.otcsignal.com) is a stock watch website that provides free daily alerts on stocks. OTC Signal's alerts include news releases or daily e-mails on stocks in all sectors of the market. These include stocks with high or low volume, penny stocks, stocks with technical indicators and much more. OTC Signal tracks stocks that may be moving upwards or downwards. OTC Signal also features companies on its website with company profiles, research reports, analysis, and newsletters.
OTC Signal is an independent electronic publication that provides information on selected publicly traded companies. OTC Signal is not a registered investment advisor or broker-dealer. OTC Signal including affiliates, officers, directors, contractors and employees may buy, sell or hold shares in any company mentioned herein and may profit in the event those shares increase or decrease in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.
To join and start receiving our FREE e-mail alerts and newsletter, please visit: http://www.otcsignal.com
Disclaimers-
Release of Liability: Through use of this website viewing or using you agree to hold OTCSignal.com, its operators, owners, and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities.
The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTC Signal encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTC Signal makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTC Signal has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTC Signal also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in any stock (large-cap, small-cap, or micro-cap security) is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTC Signal makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCSignal.com. OTC Signal owners may or may not hold positions in any of the companies that are profiled.
SAFE HARBOR: The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. These statements are not guarantees of future performance and involve significant risks and uncertainties. Actual results may vary materially from those in the forward-looking statements. Factors that could cause actual results to differ include but are not limited to; the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, the effectiveness of management's strategies and decisions, general economic and business conditions, new or modified statutory or regulatory requirements and changing price and market conditions. Investing in securities is speculative and carries risk. Past performance does not guarantee future results. No assurance can be given that these are all the factors that could cause actual results to vary materially from the forward-looking statements. The following report is neither an offer to buy or sell securities. Never invest in any stock featured on the OTC Signal Stock Watch website unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list.
OTC Signal
Daily Alert
-
New York, NY 10001
USA
Phone: -
Note: The following news is from Daily Alert, and World Stock Wire, Inc. is not liable for the contents of this news.
(C) 2011 World Stock Wire, Inc. All rights reserved.
-0-
expecting a pr this week!
This is so undervalued here, we should be back to .12-.16 cents a share given the current market cap. With a good press release we could be back to .50+ very easily. Locked and loaded :)
your right on top of it! something big must be developing here with the HPV tests, perhaps Allezoe came across diagnosis of a treatment for it! There has been a good amount of buying here the past week something is certainly brewing on the back end of this :)
Meritage,
you been hyping this since day one and are still here care to give any input? I am all for the other side of story, just trying to make sense of this all and not liking what i am seeing.
.25's printing! don't miss this train.
Ask: .0249 this was .60 cents a few months back don't miss the boat!
Today's alerts include: Allezoe Medical Holdings, Inc. (OTCBB: ALZM)
Allezoe Medical Holdings, Inc. recently announced that it has acquired the exclusive license to develop and market patent pending, advanced "see and treat" diagnostic technology for Human papillomavirus (HPV), the world's leading sexually transmitted infection (STI). An exclusive license has been signed by SureScreen Medical, Inc., a wholly-owned subsidiary of Allezoe, and AVM Corp., which recently acquired the technology and the pending patent application from its developer, Aequorea Vision Medical, Inc.
Under the terms of the license, SureScreen will develop and market products worldwide using the technology in return for a fixed royalty to AVM, commencing on sales of products using the technology.
As a result of the license, Allezoe now holds the exclusive worldwide rights to this groundbreaking "see and treat" technology which will allow healthcare providers to identify cell damage from HPV instantaneously, bypassing the long lab wait times, fees and additional patient discomfort found in existing HPV diagnostic methods on the market, including the Pap smear.
With this license and the global marketing and distribution strategy it is developing, Allezoe will be positioned to enter its market. In the United States alone, there is a $6 billion annual diagnosis and treatment market for HPV, and the market is increasing under growing national attention to the virus. Recently, the Centers for Disease Control and Prevention has recommended the HPV vaccine be used for men as well. Allezoe's technology is a crucial counterpart to the vaccine, identifying any preexisting damage before vaccine administration; importantly, it also offers an important alternative for those who avoid the vaccine due to controversial side effects.
Infecting 233 million women worldwide, the virus is the leading cause of cervical cancer in women, which often results in death. HPV is known to cause a growing number of cancers and lesions in both genders, including cervical, neck, and throat cancer. More recently, HPV is being researched as a possible cause of heart disease. Allezoe's technology is a one-stop HPV solution for patients and their providers. Allezoe's HPV technology will be welcome in the United States, where healthcare costs are a growing concern. It has important implications for healthcare abroad and in poorer nations where patients do not have the luxury of making repeated visits to a clinic or waiting several days for a Pap smear report from a distant laboratory.
Allezoe Medical Holdings, Inc. is a holding company focused on acquiring the most high quality and in-demand medical products, solutions and services. Whether through diagnosis, treatment, or medical research itself, Allezoe is interested in companies that are making a striking difference in the healthcare system through technology and treatments for health issues that affect large populations.
For more information, please visit www.allezoe.com.
ABOUT OTC Signal
OTC Signal (www.otcsignal.com) is a stock watch website that provides free daily alerts on stocks. OTC Signal's alerts include news releases or daily e-mails on stocks in all sectors of the market. These include stocks with high or low volume, penny stocks, stocks with technical indicators and much more. OTC Signal tracks stocks that may be moving upwards or downwards. OTC Signal also features companies on its website with company profiles, research reports, analysis, and newsletters.
OTC Signal is an independent electronic publication that provides information on selected publicly traded companies. OTC Signal is not a registered investment advisor or broker-dealer. OTC Signal including affiliates, officers, directors, contractors and employees may buy, sell or hold shares in any company mentioned herein and may profit in the event those shares increase or decrease in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.
To join and start receiving our FREE e-mail alerts and newsletter, please visit: http://www.otcsignal.com
Disclaimers-
Release of Liability: Through use of this website viewing or using you agree to hold OTCSignal.com, its operators, owners, and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities.
The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTC Signal encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTC Signal makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTC Signal has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTC Signal also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in any stock (large-cap, small-cap, or micro-cap security) is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTC Signal makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCSignal.com. OTC Signal owners may or may not hold positions in any of the companies that are profiled.
SAFE HARBOR: The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. These statements are not guarantees of future performance and involve significant risks and uncertainties. Actual results may vary materially from those in the forward-looking statements. Factors that could cause actual results to differ include but are not limited to; the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, the effectiveness of management's strategies and decisions, general economic and business conditions, new or modified statutory or regulatory requirements and changing price and market conditions. Investing in securities is speculative and carries risk. Past performance does not guarantee future results. No assurance can be given that these are all the factors that could cause actual results to vary materially from the forward-looking statements. The following report is neither an offer to buy or sell securities. Never invest in any stock featured on the OTC Signal Stock Watch website unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list.
OTC Signal
Daily Alert
-
New York, NY 10001
USA
Phone: -
Note: The following news is from Daily Alert, and World Stock Wire, Inc. is not liable for the contents of this news.
(C) 2011 World Stock Wire, Inc. All rights reserved.
-0-
http://www.otcmarkets.com/stock/ALZM/news